Improving outcomes for older patients receiving allogeneic transplants through exercise
Intervening on Frailty to Improve Outcomes for Older Allogeneic Transplant Recipients
NA · Abramson Cancer Center at Penn Medicine · NCT05612789
This study is testing if a supervised exercise program can help older adults recover better after receiving a stem cell transplant.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 72 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Abramson Cancer Center at Penn Medicine (other) |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT05612789 on ClinicalTrials.gov |
What this trial studies
This interventional pilot study aims to assess the feasibility of a supervised exercise program for older adults undergoing allogeneic hematopoietic cell transplantation (HCT). The study will enroll 60-72 participants who will be divided into two cohorts: one for prehabilitation before the transplant and another for rehabilitation after the transplant. The primary focus is to evaluate whether this exercise intervention can enhance recovery and overall outcomes for these patients.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 60 years or older with a planned allogeneic HCT and a diagnosis of hematological malignancy.
Not a fit: Patients with comorbid disabilities or illnesses that prevent safe exercise will not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve recovery and health outcomes for older patients undergoing allogeneic transplants.
How similar studies have performed: While this approach is novel in the context of allogeneic transplantation, similar exercise interventions have shown promise in improving outcomes in other patient populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Cohort A (Prehab) 1. Age 60 years or older. 2. Planned allogeneic HCT in the next 1-6 months. 3. Hematological malignancy as the indication for HCT. 4. Pre-frail or frail by Fried frailty phenotype. Cohort B (Rehab) 1. Age 60 years or older. 2. Planned allogeneic HCT or HCT within the last 30 days. 3. Hematological malignancy as the indication for HCT. Exclusion Criteria: Cohorts A and B 1\. Comorbid disability or illness that prevents safe exercise.
Where this trial is running
Philadelphia, Pennsylvania
- Penn Medicine — Philadelphia, Pennsylvania, United States (RECRUITING)
Study contacts
- Principal investigator: Shannon McCurdy, MD — Penn Medicine
- Study coordinator: Jacqui Rick
- Email: Jacqui.Rick@pennmedicine.upenn.edu
- Phone: 2152209675
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Allogeneic Transplantation